Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide Dose Comparison in Limited SCLC
NCT00002858Phase 3Unknown
- Sponsor
- Gustave Roussy
- Start
- Mar 1993
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclophosphamide in small cell lung cancer (SCLC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Disease-Free Survival at 2 years. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00002858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002858.